🔗 Share this article

While the United States proceeds with historic changes to its vaccine schedules, a particular individual has surfaced in a surprising turn: Høeg, a Danish American physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations throughout the pandemic and has concentrated on possible fatalities after Covid vaccination in her recent position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Program

Agency leaders had intended to unveil radical revisions to the childhood vaccine schedule in December, bringing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of alignment with a large portion of the international standard with no evidence for benefit. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A New Direction at the Agency

The acting appointment might represent a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain childhood shot schedules in the US so as to align more in line with Denmark's approach, a society with comprehensive healthcare and a population about the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – traditionally the purview of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Questions Over Expertise

Høeg has no obvious experience in drug development, approval processes or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since March.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in leading a sizeable institution. She is not an expert in industry regulation.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the science of medication creation”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who ran the center have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock stated.

“Many people just zeroes in on the new drug program, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those need to be managed,” Dr. Woodcock explained. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the position, which manages more than 5,000 personnel. “It is a massive leadership role, if you perform it correctly,” the former official said.

Agency Reaction and Controversial Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this selection indicates greater collaboration among FDA leaders on immunizations, a representative stated that the “inquiries stem from incorrect assumptions”.

“Her experience aligns with the responsibilities of her job,” the official said, pointing to the time Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's recently launched fast-track approval initiative, a controversial rapid drug-approval program that allegedly troubled her preceding directors. “How are these medications being selected for this fast-track system? Who makes the decisions?” Dr. Howard asked. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he remarked, “the agency appears to be shifting towards laxer rules of most medications, with the exception of immunizations.”

Established History on Vaccines

With immunizations, Dr. Høeg has a more documented, if troubling, history, Howard said. She authored a analysis using unconfirmed public submissions to determine the frequency of myocarditis following COVID-19 vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the current government featured revising rules for recently developed shots and discontinuing “unnecessary” vaccines, she stated post-election on a online show. At the FDA, Høeg has allegedly suggested excluding adolescent males from obtaining COVID-19 vaccines.

“She is an thorough dogmatist who commences with her conclusions and reverse-engineers to accommodate the data in a highly disingenuous, dishonest fashion,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|